EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Deprescribing: A Prime Opportunity to Optimize Care of Cancer Patients

Genevieve Chaput, Hitesh Bhanabhai

Current Oncology · 02.11.2023 · 30 (11) · 9701-9709

DOI: 10.3390/curroncol30110704 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Oncology, online erschienen am 02.11.2023. Verfasst von Genevieve Chaput und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Supportive and Palliative Care, McGill University Health Centre, Department of Family Medicine, McGill University, Montreal, QC H4A 3J1, …. Hauptthemen laut MEDLINE: Deprescriptions, Drug-Related Side Effects and Adverse Reactions, Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients with incurable cancers have an increasing number of comorbidities, which can lead to polypharmacy and its associated adverse events (drug-to-drug interaction, prescription of a potentially inappropriate medication, adverse drug event). Deprescribing is a patient-centered process aimed at optimizing patient outcomes by discontinuing medication(s) deemed no longer necessary or potentially inappropriate. Improved patient quality of life, risk reduction of side effects or worse clinical outcomes, and a decrease in healthcare costs are well-documented benefits of deprescribing. Deprescribing and advance care planning both require consideration of patients’ values, preferences, and care goals. Here, we provide an overview of comorbidities and associated polypharmacy risks in cancer patients, as well as useful tools and resources for deprescribing in daily practice, and we shed light on how deprescribing can facilitate advance care planning discussions with patients who have advanced cancer or a limited life expectancy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DeprescriptionsDrug-Related Side Effects and Adverse ReactionsNeoplasmsHumansPolypharmacyQuality of Life

Stichwörter der Autor:innen

advance care planningcomorbiditiesdeprescribinggoals of carepatient-centered carepolypharmacy

Autor:innen und Institutionen

  • Division of Supportive and Palliative Care, McGill University Health Centre, Department of Family Medicine, McGill University, Montreal, QC H4A 3J1, Canada.

Zitieren

APA

Chaput, G., & Bhanabhai, H. (2023). Deprescribing: A Prime Opportunity to Optimize Care of Cancer Patients. Current Oncology, 30(11), 9701-9709. https://doi.org/10.3390/curroncol30110704

Vancouver

Chaput G, Bhanabhai H. Deprescribing: A Prime Opportunity to Optimize Care of Cancer Patients. Current Oncology. 2023;30(11):9701-9709. doi:10.3390/curroncol30110704

BibTeX
@article{Chaput2023,
  author = {Chaput, Genevieve and Bhanabhai, Hitesh},
  title = {Deprescribing: A Prime Opportunity to Optimize Care of Cancer Patients},
  journal = {Current Oncology},
  year = {2023},
  volume = {30},
  number = {11},
  pages = {9701--9709},
  doi = {10.3390/curroncol30110704}
}
Kostenlos starten →